BioNTech Announces Third Quarter 2021 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
BioNTech (BNTX) PT Lowered to $289 at Goldman Sachs
November 11, 2021 7:19 AM ESTGoldman Sachs analyst Chris Shibutani lowered the price target on BioNTech (NASDAQ: BNTX) to $289.00 (from $433.00) while maintaining a Neutral rating.
The analyst commented, "While vaccine marketplace trends continue to provide tailwinds for mRNA-vaccine manufacturers, more hesitant management commentary around the endemic phase... More
BioNTech SE (BNTX) Reports Q3 EPS of EUR12.35
November 9, 2021 6:47 AM ESTBioNTech SE (NASDAQ: BNTX) reported Q3 EPS of EUR12.35, versus (EUR0.88) reported last year. Revenue for the quarter came in at EUR6.09 billion, versus EUR67.5 million reported last year.
Guidance:
Estimated BioNTech COMIRNATY/COVID-19 vaccine revenues for the full 2021... More
